Esta publicación también está disponible en: English Español
The Federal Commission for the Protection against Sanitary Risks (Cofepris) announced the approval of the Jynneos vaccine in Mexico for use against Mpox (formerly known as Monkey pox) in adults 18 and older.
The vaccine is intended for those at high risk of exposure to the virus and is not recommended for the general public, including children, pregnant, or breastfeeding women.
With this approval, pharmacies and clinics could place orders for the vaccine. For public health, the government must provide a budget allocation, which could occur in the budget for the next year.
Cofepris rigorously evaluated data submitted by Bavarian Nordic, the vaccine’s manufacturer, and confirmed it meets safety, quality, and efficacy standards.
Mpox Transmission and Symptoms
Mpox is characterized by a painful rash, typically appearing on the face, hands, and feet. The virus spreads primarily through direct contact with infected skin lesions, scabs, or bodily fluids. It can also spread through respiratory droplets.
Symptoms can develop 5-21 days after exposure and may include:
- Headache
- Fever (above 38°C)
- Rash or skin lesions
- Back pain
- Swollen or painful lymph nodes
- Muscle aches
Individuals with untreated HIV, other sexually transmitted infections, weakened immune systems (due to cancer treatment or immunosuppressants), pregnant women, and children are at higher risk of complications.
Vaccination and Reporting
The Jynneos vaccine must be administered under medical supervision and should not be taken indiscriminately. Potential side effects can be reported by email (farmacovigilancia@cofepris.gob.mx) or through the Cofepris website.
Cofepris remains committed to proactive regulation and ensuring the safety of health supplies. This approval allows for faster access to the Jynneos vaccine for high-risk adults in Mexico.
Related Stories:
Esta publicación también está disponible en: English Español
